CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenues:
Total revenues	$ 534,726	$ 508,186
Operating expenses:
Cost of product sales (excluding amortization of acquired developed technologies)	28,657	33,506
Selling, general and administrative	208,400	167,947
Research and development	86,107	60,105
Intangible asset amortization	62,847	56,885
Acquired in-process research and development	202,250	56,000
Impairment charge	136,139	0
Total operating expenses	724,400	374,443
Income (loss) from operations	(189,674)	133,743
Interest expense, net	(18,496)	(17,922)
Foreign exchange loss	(1,132)	(611)
Income (loss) before income tax provision (benefit) and equity in loss (gain) of investees	(209,302)	115,210
Income tax provision (benefit)	(51,287)	29,116
Equity in loss (gain) of investees	(182)	893
Net income (loss)	$ (157,833)	$ 85,201
Net income (loss) per ordinary share:
Basic (in dollars per share)	$ (2.82)	$ 1.49
Diluted (in dollars per share)	$ (2.82)	$ 1.47
Weighted-average ordinary shares used in per share calculations - basic (in shares)	55,956	57,206
Weighted-average ordinary shares used in per share calculations - diluted (in shares)	55,956	58,081
Product sales, net
Revenues:
Total revenues	$ 530,205	$ 503,331
Royalties and contract revenues
Revenues:
Total revenues	$ 4,521	$ 4,855